Resultados de investigación

The stain was released on the cutting plan (top). Internal wing on the left, the external ones on the right., Peer reviewed

The stain was released on the cutting plan (top). Internal wing on the left, the external ones on the right., Peer reviewed

Este conjunto de datos esta sujeto a una licencia CC BY 4.0, Peer reviewed

File with schemas from the original article., Sugars are a versatile tool for targeting malignant cells and have been extensively used for drug delivery and imaging techniques. Their prototype, fluorodeoxyglucose ([18F]FDG), is currently used for positron emission tomography. Boron neutron capture therapy (BNCT) is a cancer treatment that relies on irradiation with thermal neutrons of cancer cells previously loaded with [10B]-containing compounds. The recent introduction of accelerators as a neutron source for clinical use prompts the planning of delivery compounds enriched with boron able to be traced in real time. This work describes the first synthesis of a new class of sugar derivatives conjugated to a trifluoroborate moiety as potential theranostic agents. Stability and cytotoxicity studies are reported for all compounds, together with [18F] radiolabeling optimization and in vivo preliminary positron emission tomography (PET) experiments on a selected compound., Peer reviewed

1 figure, CKD: Chronic kidney disease; PN: Pyelonephritis; SB/C: Subclinical bacteriuria/Cystitis; UO: Ureteral obstruction, Peer reviewed

A. PCA of urine samples on the basis of normalized read counts of the known and putative novel miRNAs for the 38 samples initially processed. The red arrows indicate the outlier Control samples (C5, C6 and C7). B. PCA excluding the high outlier samples. CKD: Chronic kidney disease; PN: Pyelonephritis; SB/C: Subclinical bacteriuria/Cystitis; UO: Ureteral obstruction., Peer reviewed

A. Proportion of samples for which each of the known miRNAs across the different groups were detected. B. Cumulative abundance of the known feline miRNAs. The dots indicate the log10 of the miRNA abundance for each miRNA. miRNAs are sorted in each group in a decreasing order by their miRNA abundance on the x-axis, independently for each group. C. Proportion of samples for which each of the putative novel miRNA candidates across the different groups were detected. D. Cumulative abundance of the putative novel miRNAs. The dots indicate the log10 of the miRNA abundance for each miRNA. miRNAs are sorted in each group in a decreasing order by their miRNA abundance on the x-axis, independently for each group. CKD: Chronic kidney disease; PN: Pyelonephritis; SB/C: Subclinical bacteriuria/Cystitis; UO: Ureteral obstruction, CPM: Counts per million., Peer reviewed

1 figure., All samples together (all groups), as well as each one of the contrasts considered (Controls vs. PN; Control vs. SB/C; Control vs. UO; Control vs. CKD; PN vs. SB/C; PN vs. UO; PN vs. CKD and PN vs. other Pathologies) are shown. CKD: Chronic kidney disease; PN: Pyelonephritis; SB/C: Subclinical bacteriuria/Cystitis; UO: Ureteral obstruction., Peer reviewed

1 figure., CKD: Chronic kidney disease; PN: Pyelonephritis; SB/C: Subclinical bacteriuria/Cystitis; UO: Ureteral obstruction, CPM: Counts per million, Rq: Relative quantities., Peer reviewed

The data presented is from selected miRNAs that were DA (|log2FC| ≥ 1.5 for qPCR and |log2FC| ≥ 2 for small RNAseq; q-value < 0.05) using both methodologies. CKD: Chronic kidney disease; PN: Pyelonephritis; SB/C: Subclinical bacteriuria/Cystitis; UO: Ureteral obstruction, CPM: Counts per million, Rq: Relative quantities., Peer reviewed